ArticleArthritis research & therapy2007
Toll-like receptors and innate immune responses in systemic lupus erythematosus.
Article in Arthritis research & therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 60 citations in OpenAlex.
- IRF5 Controls Plasma Cell Generation and Antibody Production via Distinct Mechanisms Depending on the Antigenic Trigger.Immunology · 2025Article
- Rare Cutaneous Side Effects of Imiquimod: A Review on Its Mechanisms, Diagnosis, and Management.Dermatology and therapy · 2023Review
- Mesenchymal stem cell-derived exosome-educated macrophages alleviate systemic lupus erythematosus by promoting efferocytosis and recruitment of IL-17Stem cell research & therapy · 2022Article
- Conditionally Controlling Human TLR2 Activity via Trans-Cyclooctene Caged Ligands.Bioconjugate chemistry · 2020Article
- Cell-free synthesis of human toll-like receptor 9 (TLR9): Optimization of synthesis conditions and functional analysis.PloS one · 2019Article
- Platelets in Skin Autoimmune Diseases.Frontiers in immunology · 2019Review
- Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.Paediatric drugs · 2016Review
- The macrophages in rheumatic diseases.Journal of inflammation research · 2016Review
- Innate immune pattern recognition: a cell biological perspective.Annual review of immunology · 2015Review
- Article
- The danger of sex and death in Scarf1(-/-) autoimmune mice.Nature immunology · 2013Article
- Contribution of toll-like receptor 9 gene single-nucleotide polymorphism to systemic lupus erythematosus.Rheumatology international · 2013Article
- EBI2 is a negative regulator of type I interferons in plasmacytoid and myeloid dendritic cells.PloS one · 2013Article
- Altered IL-10 and TNF-α production in peripheral blood mononuclear cells of systemic lupus erythematosus patients after Toll-like receptor 2, 4, or 9 activation.Clinical and experimental medicine · 2012Article
- Estrogen receptor alpha modulates Toll-like receptor signaling in murine lupus.Clinical immunology (Orlando, Fla.) · 2012Article
- Toll-like receptors in systemic lupus erythematosus: potential targets for therapeutic intervention.Current allergy and asthma reports · 2012Review
- Are Toll-like receptors and decoy receptors involved in the immunopathogenesis of systemic lupus erythematosus and lupus-like syndromes?Clinical & developmental immunology · 2012Review
- Microparticles as a source of extracellular DNA.Immunologic research · 2011Article
- The role of innate immunity in donor organ procurement.Seminars in immunopathology · 2011Review
- Targeting Toll-like receptors for treatment of SLE.Mediators of inflammation · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of discoveries over the past several years has provided a new paradigm for understanding autoimmunity in systemic lupus erythematosus. The discoveries of pattern recognition receptors and of how these receptors can be recruited into autoimmune responses underpin this paradigm. The implications of these observations continue to unfold with ongoing investigation into the range and specificity of pattern recognition receptors, into how immune complexes containing nucleic acids trigger these receptors, into how endogenous macromolecular 'danger signals' stimulate innate immune responses, and into the effect of pattern recognition receptor activation on various cell types in initiating and perpetuating autoimmunity. The development of clinical trials using therapeutic agents that target components of the innate immune system suggests that these advances may soon culminate in new medications for treating patients with systemic lupus erythematosus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.